HPTN Studies

Our studies strive to prevent HIV acquisition and transmission through the use of antiretroviral drugs, interventions for substance use, behavioral risk reduction, and structural interventions. 

HPTN research studies are developed by protocol teams that include CTU investigators and recognized experts in HIV prevention. As study protocols are developed, they undergo a rigorous intra- and extra-Network review process that ensures compliance with current ethical guidelines and regulatory procedures. Each Study Protocol is available once version 1.0 is approved and distributed to the performance sites.

Study Snapshot

Study Timelines

 

Filter studies by:

HVTN 140/HPTN 101 (154188)

A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PGDM1400LS alone and in combination with VRC07-523LS and PGT121.414.LS in healthy, HIV-uninfected adult participants

Closed to Follow Up

Antibody Mediated Prevention

CoVPN 5002 (38749)

SARS-CoV-2 Prevalence Survey

Closed to Follow Up

COVID-19

HPTN 083-02 (38645)

Factors Influencing Adherence to Injectable PrEP and Retention in an Injectable PrEP Research Study

Closed to Follow Up

PrEP

HPTN 096 (38561)

Getting to Zero Among Black MSM in the American South: Testing the Efficacy of an Integrated Intervention Strategy

Temporarily Closed (Paused) to Accrual

Integrated Strategy

HVTN 804/HPTN 095 (38632)

Antiretroviral analytical treatment interruption (ATI) to assess immunologic and virologic responses in participants who received VRC01 or placebo and became HIV-infected during HVTN 704/HPTN 085

Closed to Follow Up

Other

HPTN 094 (38715)

INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care.

Participants Off Study and Primary Analysis Completed

Integrated Strategy

HVTN 805/HPTN 093 (38691)

Antiretroviral analytical treatment interruption (ATI) to assess immunologic and virologic responses in participants who initiated ART in early HIV infection after having received VRC01 or placebo in HVTN 703/HPTN 081

Closed to Follow Up

Other

HPTN 084-01 (38655)

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV among Adolescent Females – A Sub-study of HPTN 084

Closed to Follow Up

PrEP